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ECONOMIC BURDEN OF OSTEOPOROSIS,
BREAST CANCER,AND CARDIOVASCULAR
DISEASE AMONG WOMEN
Sasser A1, Birnbaum HG1, Oster EF1, Rousculp M2
1Analysis Group/Economics, Boston, MA, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVES: To investigate the ﬁnancial burden of
osteoporosis, breast cancer, and cardiovascular disease
among women age 50 to 64 years in terms of the direct
health care and indirect work-loss costs to an employer.
METHODS: Administrative medical and disability claims
data from seven large employers (n > 600,000) were ana-
lyzed between 1998 and 2000. Patients were identiﬁed as
female beneﬁciaries, age 50 to 64 years, who were
enrolled in a managed indemnity health plan. Treatment
samples were deﬁned using ICD-9 codes to identify prin-
cipal diagnoses for each of the three study conditions and
then compared to a random sample of women, age 50 to
64 years. RESULTS: For the year 2000, osteoporosis
patients had direct medical care costs that were $2277
greater than those for the random sample ($4543 versus
$2266, P < 0.05). For breast cancer, the difference was
$12,379 (P < 0.05), with hospital outpatient costs
accounting for the largest share of total costs (43%). For
cardiovascular disease the difference was $12,814 (P <
0.05), with hospital inpatient costs accounting for the
largest share of total costs (48%). The average number
of medical claims per patient was 18.6 for the random
sample, compared to 38.4 for osteoporosis patients, 76.0
for breast cancer patients, and 67.0 for cardiovascular
patients (P < 0.05). Ongoing research will control for
demographic characteristics using multivariate regression
and also explore differences in medically related work
absence costs. CONCLUSIONS: Women beneﬁciaries,
age 50 to 64 years, treated for osteoporosis, breast cancer,
and cardiovascular disease impose a signiﬁcant ﬁnancial
burden on employers. This burden is due to higher levels
of both inpatient and outpatient health care utilization
compared to a random sample of similar patients.
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THE LIFETIME MEDICAL COSTS OF WOMEN:
CARDIOVASCULAR DISEASE, DIABETES,AND
STRESS URINARY INCONTINENCE
Birnbaum H, Leong S, Kabra A
Analysis Group/Economics, Boston, MA, USA
OBJECTIVE: The purpose of this study was to generate
the ﬁrst estimates of the lifetime medical costs of treating
women with either cardiovascular disease (“CVD”), 
diabetes, or stress urinary incontinence (“SUI”).
METHODS: Women under age 65 years, who have been
treated for CVD, diabetes, or SUI, were identiﬁed using
administrative medical claims data from a large employer
(n > 100,000). A case-control methodology was used 
to estimate the annual medical costs of these women.
Annual estimates were then calculated for women 65
years and older based on a set of assumptions and pub-
lished government statistics. An incidence-based method-
ology with steady-state assumptions was used to project
these annual costs to the lifetime medical costs of treat-
ing women with CVD, diabetes, or SUI. Costs are incre-
mental and are estimated as the additional costs incurred
by patients, as compared to demographically similar con-
trols without the condition. The methodology used does
not account for cost inﬂation, technological change, or
the time value of money. RESULTS: The lifetime costs
associated with CVD, diabetes, and SUI are substantial.
CVD is the most expensive condition on a lifetime basis,
followed by diabetes, and then SUI. The incremental 
lifetime medical cost of treating a woman with CVD (in
2002 dollars) is $423,000. The lifetime cost of treating 
a woman with diabetes is $233,000 and with SUI is
$58,000. CONCLUSIONS: These ﬁndings are the ﬁrst
estimates of the lifetime medical cost burden of three
chronic conditions suffered by women. The levels of these
costs suggest the need for further research and method-
ological reﬁnements to increase awareness of the lifetime
burden of chronic conditions.
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ECONOMIC IMPACT OF SILDENAFIL CITRATE
ON A PHARMACY BUDGET
Cooke C1,Wong W2, Lee H3, Duttagupta S4
1Pﬁzer Inc, Ellicott City, MD, USA; 2CareFirst BlueCross
BlueShield, Baltimore, MD, USA; 3University of Maryland
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OBJECTIVES: CareFirst BlueCross BlueShield serves 
3.1 million members in Maryland, Washington, D.C.,
Virginia, and Delaware. The organization provides pre-
scription coverage for 1.1 million members and faces 
spiraling pharmacy expenditures. There has been consid-
erable debate about insurance coverage of sildenaﬁl
citrate, and CareFirst has added this agent to the second
tier of the formulary with restriction. There is a quantity
limit of six tablets per month (or 18 tablets per three
months). However, self-funded accounts have the option
of not including this management tool as part of their pre-
scription beneﬁt. This report analyzes the economic
impact of sildenaﬁl citrate on a pharmacy’s budget.
METHODS: All prescription claims data for sildenaﬁl
citrate were obtained for the year 2001. The claims ﬁle
was imported into an Access database for abstraction of
required data. RESULTS: There were 65,222 prescription
claims for sildenaﬁl citrate in 2001, with each member (N
= 19,646) averaging 3.3 ± 2.7 prescriptions. CareFirst
spent almost $2.6 million on sildenaﬁl citrate, equating
to $2.31 per member per year (PMPY), or $0.19 per
member per month (PMPM). Thus, sildenaﬁl citrate pre-
scriptions constituted approximately 0.5% of the 2001
pharmacy budget. A total of 1.4% of prescriptions (n =
891) were written for 25-mg sildenaﬁl citrate, compared
